MediniceWAR:ICE -3.63%24 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates WAR:ICE with a GF Score™ of 24/100 and a GF Value™ of zł0.99 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Medinice ranks worse than 122699.26% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Medinice's Free Cash Flow for the
three
months ended in Mar. 2026 was zł-2.97 Mil. Medinice's Revenue for the
three
months ended in Mar. 2026 was zł0.00 Mil. Therefore, Medinice's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Medinice's FCF Margin % or its related term are showing as below:
During the past 10 years, the highest FCF Margin % of Medinice was -354.59%. The lowest was -193300.00%. And the median was -2562.60%.
WAR:ICE's FCF Margin % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -0.03 * Ranked among companies with meaningful FCF Margin % only.
Medinice FCF Margin % Related Terms
Medinice FCF Margin % Historical Data
* Premium members only.
The historical data trend for Medinice's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medinice's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinice FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medinice's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Medinice's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinice (WAR:ICE) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medinice and its competitors. According to the industry distribution chart, Medinice ranks #999999 out of 815 companies in the Medical Devices & Instruments industry.
Is Medinice's FCF Margin % too high?
Medinice's current FCF Margin % is 0.00%. Based on the distribution chart, Medinice ranks #999999 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medinice has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medinice's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medinice ranks #999999 out of 815 companies for FCF Margin %. This places Medinice in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medinice and its competitors. Medinice's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinice stock overvalued right now?
Based on GuruFocus' analysis, Medinice (WAR:ICE) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.99, compared to a current price of zł69.00 — trading 6869.7% above its estimated fair value. The current FCF Margin % is 0.00%. Medinice's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Medinice (WAR:ICE), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinice (WAR:ICE) Overvalued in 2026?
Based on GuruFocus' analysis, Medinice stock appears to be overvalued.
The current stock price of zł69.00 is trading 6869.7% above its estimated GF Value™ of zł0.99.
GuruFocus considers Medinice to be Significantly Overvalued.
Key valuation signals for WAR:ICE:
FCF Margin %: 0.00%
GF Value™: zł0.99 vs. price of zł69.00 (6869.7% above fair value)
No single metric tells the full story. See the WAR:ICE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinice SA is a Polish company operating in the MedTech industry. The company is engaged in creating, developing and commercializing solutions in the field of medicine, in particular, cardiology and cardio surgery. Its portfolio includes close around 12 projects including CathAIO, an electrode with universal diagnostic, electrophysiological, haemodinamic and biohemic functions and can be used for RF ablation; cryoapplicator, for minimally invasive cardiosurgical cryoablation; Med-iConsole allows to reduce the need to use multiple computer devices during electrophysiological treatment; Minimax and Pacepress.
24GF Score
Get the complete analysis for WAR:ICE
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:ICE has been successfully added to your 
